Viking Therapeutics Inc (NASDAQ: VKTX) on Monday, plunged -3.76% from the previous trading day, before settling in for the closing price of $32.75. Within the past 52 weeks, VKTX’s price has moved between $22.51 and $99.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -4.66%. With a float of $107.97 million, this company’s outstanding shares have now reached $111.43 million.
The extent of productivity of a business whose workforce counts for 27 workers is very important to gauge. In terms of profitability, gross margin is 28.9%, operating margin of -30726.61%, and the pretax margin is -22741.06%.
Viking Therapeutics Inc (VKTX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Viking Therapeutics Inc is 3.11%, while institutional ownership is 72.52%. The most recent insider transaction that took place on Jan 06 ’25, was worth 8,313,601. In this transaction President & CEO of this company sold 194,490 shares at a rate of $42.75, taking the stock ownership to the 2,366,570 shares. Before that another transaction happened on Jan 06 ’25, when Company’s Chief Operating Officer sold 54,215 for $42.75, making the entire transaction worth $2,317,599. This insider now owns 374,134 shares in total.
Viking Therapeutics Inc (VKTX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -4.66% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -26.28% during the next five years compared to -18.89% drop over the previous five years of trading.
Viking Therapeutics Inc (NASDAQ: VKTX) Trading Performance Indicators
Viking Therapeutics Inc (VKTX) is currently performing well based on its current performance indicators. A quick ratio of 36.47 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.94, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.49 in one year’s time.
Technical Analysis of Viking Therapeutics Inc (VKTX)
The latest stats from [Viking Therapeutics Inc, VKTX] show that its last 5-days average volume of 2.88 million was inferior to 3.57 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 35.46%. Additionally, its Average True Range was 2.24.
During the past 100 days, Viking Therapeutics Inc’s (VKTX) raw stochastic average was set at 1.88%, which indicates a significant decrease from 12.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.72% in the past 14 days, which was lower than the 77.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $42.74, while its 200-day Moving Average is $57.05. Now, the first resistance to watch is $32.24. This is followed by the second major resistance level at $32.95. The third major resistance level sits at $33.51. If the price goes on to break the first support level at $30.97, it is likely to go to the next support level at $30.41. The third support level lies at $29.70 if the price breaches the second support level.
Viking Therapeutics Inc (NASDAQ: VKTX) Key Stats
Market capitalization of the company is 3.51 billion based on 111,436K outstanding shares. Right now, sales total 0 K and income totals -85,900 K. The company made 0 K in profit during its latest quarter, and -24,940 K in sales during its previous quarter.
